Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
Andersen G, Meiffren G, Famulla S, Heise T, Ranson A, Seroussi C, Eloy R, Gaudier M, Charvet R, Chan YP, Soula O, DeVries JH. Andersen G, et al. Among authors: meiffren g. Diabetes Obes Metab. 2021 Apr;23(4):961-970. doi: 10.1111/dom.14302. Epub 2021 Jan 18. Diabetes Obes Metab. 2021. PMID: 33336850
Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T. Andersen G, et al. Among authors: meiffren g. Diabetes Obes Metab. 2018 Nov;20(11):2627-2632. doi: 10.1111/dom.13442. Epub 2018 Jul 12. Diabetes Obes Metab. 2018. PMID: 29923294 Clinical Trial.
BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode B. Heise T, et al. Among authors: meiffren g. Diabetes Obes Metab. 2019 Apr;21(4):1066-1070. doi: 10.1111/dom.13621. Epub 2019 Jan 17. Diabetes Obes Metab. 2019. PMID: 30565407 Clinical Trial.
Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes.
Meiffren G, Herbrand T, Anastassiadis E, Klein O, DeVries JH, Heise T, Alluis B, Mégret C, Gaudier M, Soula O, Plum-Mörschel L. Meiffren G, et al. Diabetes Obes Metab. 2019 Jul;21(7):1570-1575. doi: 10.1111/dom.13685. Epub 2019 Apr 8. Diabetes Obes Metab. 2019. PMID: 30828929 Clinical Trial.
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.
Andersen G, Eloy R, Famulla S, Heise T, Meiffren G, Seroussi C, Gaudier M, Mégret C, Chan YP, Soula O, Riddle M. Andersen G, et al. Among authors: meiffren g. Diabetes Obes Metab. 2023 May;25(5):1241-1248. doi: 10.1111/dom.14972. Epub 2023 Jan 31. Diabetes Obes Metab. 2023. PMID: 36633505 Clinical Trial.
The potential of targeting TREM-1 in IBD.
Vinolo E, Maillefer M, Jolly L, Colné N, Meiffren G, Carrasco K, Derive M. Vinolo E, et al. Among authors: meiffren g. Adv Pharmacol. 2024;101:301-330. doi: 10.1016/bs.apha.2024.10.010. Epub 2024 Oct 24. Adv Pharmacol. 2024. PMID: 39521605 Review.
Identification of human skin bacteria attractive to the Asian Tiger mosquito.
Michalet S, Minard G, Chevalier W, Meiffren G, Saucereau Y, Tran Van V, Comte G, Tran FH, Valiente Moro C. Michalet S, et al. Among authors: meiffren g. Environ Microbiol. 2019 Dec;21(12):4662-4674. doi: 10.1111/1462-2920.14793. Epub 2019 Sep 12. Environ Microbiol. 2019. PMID: 31464044
21 results